The Effect of Autologous Autovaccine in Patients With Allergy on House-dust-mite (FIAVS)

This study has been completed.
Information provided by:
Johann Wolfgang Goethe University Hospitals Identifier:
First received: May 12, 2008
Last updated: December 28, 2010
Last verified: May 2008
House dust mite allergy is a common problem, resulting in asthma, chronic swelling of the eyes, and running nose. The investigators test a possibility to immunize subjects sensitized against house dust mite with extracts from their own gut bacteria "auto-vaccination".

Condition Intervention Phase
Allergens, House Dust Mites
Biological: Injection of autovaccine (Autovaccine Symbiopharm)
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Frankfurt Investigator-initiated Autovaccine-study

Resource links provided by NLM:

Further study details as provided by Johann Wolfgang Goethe University Hospitals:

Primary Outcome Measures:
  • Patients' clinical parameters and behaviour, laboratory values [ Time Frame: jul 2006 - august 2008 ] [ Designated as safety issue: Yes ]
  • laboratory testing reflecting function of bone marrow, liver, kidney [ Time Frame: jul 2006- august 2008 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Lung function,exhalative NO [ Time Frame: jul 2006 - oct 2007 ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: July 2006
Study Completion Date: December 2010
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A
house dust mite allergics will undergo autovaccine immunization
Biological: Injection of autovaccine (Autovaccine Symbiopharm)
increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
Other Name: Autovaccine Symbiopharm

Detailed Description:
see above

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • informed consent
  • age 18-35 years
  • known allergy on house-dust mite
  • GINA 0-1

Exclusion Criteria:

  • anamnestic incompatibility to parts of autovaccine
  • asthma > GINA I°
  • chronic disease conditions or infections
  • pregnancy
  • inhalative or systemic steroid use
  • any immunosuppressive therapy
  • intake of any other probiotic medication (e.g. E.coli nissle 1917)
  • participation in any other study at the same time
  • substance abuse
  • Incapability of understanding the study's purpose and performance
  • smoker
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00677209

Goethe University, Department of Pulmonology
Frankfurt, Hessen, Germany, 60590
Sponsors and Collaborators
Johann Wolfgang Goethe University Hospitals
Principal Investigator: Stefan Zielen, M.D., Ph.D. Goethe University, Department of pulmonology
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Prof Stefan Zielen, Childrens Hospital Goethe University Identifier: NCT00677209     History of Changes
Other Study ID Numbers: AVH-2004/1  Eudra-CT Nr. 2005-005534-12 
Study First Received: May 12, 2008
Last Updated: December 28, 2010
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Johann Wolfgang Goethe University Hospitals:
house dust mite
allergy processed this record on May 05, 2016